

MEDAREX INC  
Form 8-K  
August 02, 2004

As filed with the Securities and Exchange Commission on August 2, 2004.

## **SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

### **FORM 8-K**

#### **CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

**August 2, 2004 (August 2, 2004)**

### **MEDAREX, INC.**

(Exact name of registrant as specified in its charter)

**New Jersey**  
(State of other jurisdiction  
of incorporation)

**0-19312**  
(Commission  
File Number)

**22-2822175**  
(IRS Employer  
Identification No.)

Edgar Filing: MEDAREX INC - Form 8-K

707 State Road, Princeton, N.J. 08540-1437

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(609) 430-2880**

**Not Applicable**

(Former name or former address, if changed since last report)

---

*MEDAREX, INC.*  
*TABLE OF CONTENTS*  
*FOR*  
*CURRENT REPORT ON FORM 8-K*

Item 5      Other Events

Item 7.      Financial Statements and Exhibits.

Signature

**Item 5. Other Events**

On July 13, 2004, we entered into an amendment to Collaboration and License Agreement with Gilead Sciences, Inc. (the successor in interest to NeXstar Pharmaceuticals, Inc.), referred to herein as the Gilead Amendment. Under the terms of the Gilead Amendment, we agreed to pay Gilead a total of \$8.5 million in eight equal installments of \$1,062,500, payable at our election, in cash, registered shares of our common stock or a combination thereof, in exchange for (i) a reduction of certain future royalty payment obligations, payable by us to Gilead and (ii) an expansion of the scope of certain licenses from Gilead to us relating to certain intellectual property rights regarding anti-CTLA-4 products. The first of these payments was made on August 2, 2004, through the issuance of 185,622 shares of our common stock. The seven remaining payments will be made on a quarterly basis, commencing on October 1, 2004 and ending on April 3, 2006.

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:

**Exhibit  
Number**

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDAREX, INC.  
Registrant

Date: August 2, 2004

By: /s/ Donald L. Drakeman  
Donald L. Drakeman  
President and Chief Executive Officer

**EXHIBIT INDEX**

**Exhibit  
Number**

**Description**

5

---